Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 31%
Sell 15%
Strong Sell 0%

Bulls say

CME Group reported a total revenue of $1,649 million for the quarter, marking an approximate 8.1% year-over-year increase, driven by strong demand in the Market Data segment, which grew by around 14.5% with substantial contributions from both new users and pricing adjustments. The company has shown consistent resilience in its financial performance, demonstrated by robust free cash flow generation that has allowed for increased quarterly dividend payments over 14 consecutive years, highlighting its commitment to returning value to shareholders. Additionally, CME Group has achieved a compound annual growth rate of over 7% in average daily volume (ADV) from FY16 to FY24, showcasing effective customer engagement and continuous product innovation that contributed approximately $254 million in revenue over the past five years.

Bears say

CME Group faces considerable headwinds due to expected declines in trading volume for interest rate futures coupled with pricing pressures and heightened competition, particularly from FMX. The company is forecasting a total revenue growth of approximately 5.4% year-over-year, which is below the market consensus and indicates a potential underperformance against industry expectations. Additionally, increased regulatory scrutiny poses a risk to trading volumes, further complicating the company’s financial outlook and contributing to a cautious sentiment among investors.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Feb 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $295.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $295.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.